Top

Published in:

Open Access 01-12-2010 | Research

PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects

Authors: Patrycja Kleczkowska, Piotr Kosson, Steven Ballet, Isabelle Van den Eynde, Yuko Tsuda, Dirk Tourwé, Andrzej W Lipkowski

Published in: Molecular Pain | Issue 1/2010

Abstract

Background

The clinical treatment of various types of pain relies upon the use of opioid analgesics. However most of them produce, in addition to the analgesic effect, several side effects such as the development of dependence and addiction as well as sedation, dysphoria, and constipation. One solution to these problems are chimeric compounds in which the opioid pharmacophore is hybridized with another type of compound to incease antinociceptive effects. Neurotensin-induced antinociception is not mediated through the opioid system. Therefore, hybridizing neurotensin with opioid elements may result in a potent synergistic antinociceptor.

Results

Using the known structure-activity relationships of neurotensin we have synthesized a new chimeric opioid-neurotensin compound PK20 which is characterized by a very strong antinociceptive potency. The observation that the opioid antagonist naltrexone did not completely reverse the antinociceptive effect, indicates the partial involvement of the nonopioid component in PK20 in the produced analgesia.

Conclusions

The opioid-neurotensin hybrid analogue PK20, in which opioid and neurotensin pharmacophores overlap partially, expresses high antinociceptive tail-flick effects after central as well as peripheral applications.

Available only for authorised users

Lipkowski AW, Misicka A, Hruby VJ, Carr DB: Opioid peptide analogues: Reconsideration as a potentially new generation of analgesics. Polish J Chem 1994, 68: 907–912.

Kosson D, Maszczynska Bonney I, Carr DB, Mayzner-Zawadzka E, Lipkowski AW: Antinociceptive properties of biphalin after intrathecal application in rats: a reevaluation. Pharmacol Rep 2005, 57: 545–549.PubMed

Maszczynska Bonney I, Foran SE, Marchand JE, Lipkowski AW, Carr DB: Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties. Eur J Pharmacol 2004, 488: 91–99. 10.1016/j.ejphar.2004.02.023CrossRef

Foran SE, Carr DB, Lipkowski AW, Maszczyńska I, Marchand JE, Misicka A, Beinborn M, Kopin A, Kream RM: Substance P - opioid chimeric peptide as a novel non-tolerance forming analgesic. Proc Natl Acad Sci USA 2000, 97: 7621–7626. 10.1073/pnas.130181897PubMedCentralPubMedCrossRef

Lee YS, Agnes RS, Davis P, Ma SW, Badghisi H, Lai J, Porreca F, Hruby VJ: Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem 2007, 50: 165–168. 10.1021/jm061268pPubMedCentralPubMedCrossRef

Yano K, Kimura S, Imanishi Y: Simultaneous activation of two different receptor systems by enkephalin/neurotensin conjugates having spacer chins of various lengths. Eur J Pharm Sci 1998, 7: 41–48. 10.1016/S0928-0987(98)00002-5PubMedCrossRef

Binder EB, Kinkead B, Owens MJ, Nemeroff CB: Neurotensin and dopamine interactions. Pharmacol Rev 2001, 53: 453–486.PubMed

Carraway R, Leeman SE: The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973, 248: 6854–6861.PubMed

Carraway R, Leeman SE: The amino acid sequence of a hypothalamic peptide, neurotensin. J Biol Chem 1975, 250: 1907–1911.PubMed

10.

Hermans E, Malateaux JM: Mechanism of regulation of neurotensin receptors. Pharmacol Ther 1998, 79: 89–104. 10.1016/S0163-7258(98)00009-6PubMedCrossRef

11.

Dobner PR: Neurotensin and pain modulation. Peptides 2006, 27: 2405–2414. 10.1016/j.peptides.2006.04.025PubMedCrossRef

12.

Gui X, Carraway RE, Dobner PR: Endogenous neurotensin facilitates visceral nociception and is required for stress-induced antinociception in mice and rats. Neurosci 2004, 126: 1023–1032. 10.1016/j.neuroscience.2004.04.034CrossRef

13.

Smith DJ, Hawranko AA, Monroe PJ, Gully D, Urban MO, Craig CR, Smith JP, Smith DL: Dose-dependent pain-facilitatory and -inhibitory actions of neurotensin are revealed by SR 48692, a nonpeptide neurotensin antagonist: influence on the antinociceptive effect of morphine. J Pharmacol Exper Ther 1997, 282: 899–908.

14.

Buhler AV, Proudfit HK, Gebhart GF: Neurotensin-produced antinociception in the rostral ventromedial medulla is partially mediated by spinal cord norepinephrine. Pain 2008, 135: 280–290. 10.1016/j.pain.2007.06.010PubMedCentralPubMedCrossRef

15.

Horvath G, Kekesi G: Interaction of endogenous ligands mediating antinociception. Br Res Rev 2006, 52: 69–92. 10.1016/j.brainresrev.2006.01.001CrossRef

16.

Clineschmidt BV, McGuffin JC, Bunting PB: Neurotensin: antinocisponsive action in rodents. Eur J Pharmacol 1979, 54: 129–139. 10.1016/0014-2999(79)90415-1PubMedCrossRef

17.

Holmes BB, Rady JJ, Smith DJ, Fujimoto JM: Supraspinal neurotensin-induced antianalgesia in mice is mediated by spinal cholecystokinin. Jpn J Pharmacol 1999, 79: 141–149. 10.1254/jjp.79.141PubMedCrossRef

18.

Tyler-McMahon B, Boules M, Richelson E: Neurotensin: peptide for the next millennium. Reg Peptides 2000, 93: 125–136. 10.1016/S0167-0115(00)00183-XCrossRef

19.

Boules M, Frederickson P, Richelson E: Bioactive analogs of neurotensin: focus on CNS effects. Peptides 2006, 27: 2523–2533. 10.1016/j.peptides.2005.12.018PubMedCrossRef

20.

Bruehlmeier M, Garcia-Garayoa E, Blanc A, Holzer B, Gergely S, Tourwé D, Schubiger PA, Bläuenstein P: Stabilization of neurotensin analogues: effect on peptide catabolism, biodistribution and tumor binding. Nucl Med Biol 2002, 29: 321–327. 10.1016/S0969-8051(01)00304-3PubMedCrossRef

21.

Kokko KP , Hadden MK, Price KL, Orwig KS, See RE, Dix TA: In vivo behavioural effects of stable, receptor-selective neurotensin[8–13] analogues that cross the blood-brain barrier. Neuropharmacol 2005, 48: 417–425. 10.1016/j.neuropharm.2004.10.008CrossRef

22.

Granier C, van Rietschoten J, Kitabgi P, Poustis C, Freychet P: Synthesis and characterization of neurotensin analogue for structure-activity relationship studies. Eur J Biochem 1982, 124: 117–125. 10.1111/j.1432-1033.1982.tb05913.xPubMedCrossRef

23.

Tyler BM, Douglas CL, Fauq A, Ping-Pang Y, Stewart JA, Cusack B, McCormick DJ, Richelson E: In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacol 1999, 38: 1027–1034. 10.1016/S0028-3908(99)00011-8CrossRef

24.

Kleczkowska P, Kaczorowska E, Ruszczyńska-Bartnik K, Ejchart A, Tourwé D, Lipkowski AW: Chimeric opioid-neurotensin ligands as new prospective analgesics in chronic pain. In Peptides 2008 Chemistry of Peptides in Life Science Technology and Medicine (Proceeding of the 30th European Peptide Symposium). Edited by: Lankinen H, Vallivirta J, Strandin T, Hepojoli J. FIPS, Helsinki; 2008:538–539.

25.

Garcia-Garayoa E, Bläuenstein P, Bruehlmeier M, Blanc A, Iterbeke K, Conrath P, Tourwé D, Schubiger PA: Preclinical evaluation of a new stabilized neurotensin(8–13) pseudopeptide radiolabeled with ^99m Tc. J Nucl Med 2002, 43: 374–383.PubMed

26.

Yaksh TL, Rudy TA: Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976, 17: 1031–1036. 10.1016/0031-9384(76)90029-9PubMedCrossRef

27.

Yoburn BC, Morales R, Kelly DD, Inturrisi CE: Constrain of the tail-flick assay: morphine analgesia and tolerance are dependent upon locus of tail stimulation. Life Sci 1984, 34: 1755–1762. 10.1016/0024-3205(84)90575-7PubMedCrossRef

28.

Mazella J, Vincent JP: Functional roles of the NTS2 and NTS3 receptors. Peptides 2006, 27: 2469–2475. 10.1016/j.peptides.2006.04.026PubMedCrossRef

29.

Gallagher RM, Rosenthal LJ: Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 2008,89(Suppl 1):77–82. 10.1016/j.apmr.2007.12.003CrossRef

30.

Haghparast A, Semnanian S, Fathollahi Y: Morphine tolerance and dependence in the nucleus paragigantocellularis: single unit recording study in vivo. Brain Res 1998, 814: 71–77. 10.1016/S0006-8993(98)01029-4PubMedCrossRef

Title: PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects
Authors: Patrycja Kleczkowska
Piotr Kosson
Steven Ballet
Isabelle Van den Eynde
Yuko Tsuda
Dirk Tourwé
Andrzej W Lipkowski
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Molecular Pain / Issue 1/2010
Electronic ISSN: 1744-8069
DOI: https://doi.org/10.1186/1744-8069-6-86

Keynote webinar | Spotlight on medication adherence

Springer Medicine

PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects

Abstract

Background

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2010

Expression of inwardly rectifying potassium channels by an inducible adenoviral vector reduced the neuronal hyperexcitability and hyperalgesia produced by chronic compression of the spinal ganglion

Absence of histamine-induced itch in the African naked mole-rat and "rescue" by Substance P

Trigeminal injury causes kappa opioid-dependent allodynic, glial and immune cell responses in mice

Bone cancer induces a unique central sensitization through synaptic changes in a wide area of the spinal cord

Evaluation of phenoxybenzamine in the CFA model of pain following gene expression studies and connectivity mapping

An improved behavioural assay demonstrates that ultrasound vocalizations constitute a reliable indicator of chronic cancer pain and neuropathic pain